Connect with us


Werfen Launches We Venture Capital to Invest in Diagnostic Companies

Werfen is chaired by Marc Rubiralta and in 2022 it achieved a turnover of 1.84 billion. In the largest operation in its history, the group closed the purchase of the American diagnostic company Immucor for 2 billion in March. The company’s workforce is made up of 7,000 people and its activity covers thirty countries. The company has recently launched We Venture Capital.



Werfen diversifies to continue growing in health. The Spanish group specializes in medical products and hospital supplies has created a specific division to channel its investment activity into emerging companies in the diagnostic sector, as well as digital solutions and biotechnology, which is called We Venture Capital.

With an international focus, We Venture Capital will fundamentally enter start-ups with solutions and products about to hit the market or that have just launched. It will do so primarily through series A rounds, although the vehicle will also participate in seed or series B rounds, according to the company.

We Venture Capital starts with two companies in its portfolio. The first is the Spanish DeepUll, which develops an early diagnosis of sepsis. The second company is the Belgian Axithra, which has created a platform to measure and control drug concentrations in the blood.

Read more about Werfen and the recently launched We Venture Capital fund, and find the most important business news of the day with the Born2Invest mobile app.


Werfen is chaired by Marc Rubiralta and in 2022 it achieved a turnover of 1.84 billion

We Venture Capital is led by Swedish physician and researcher Louise Warme, who joined Werfen a year ago as head of corporate venture capital. Warme came from Almi Invest, a Swedish company dedicated to investing in emerging companies.

“Our objective is to become leaders in venture capital in diagnostics; We want to thank everyone who has contributed to this launch and brought We Venture Capital to life,” says Warme. The senior chief investment officer for the new vehicle is Anthony Vallance-Owen, with 17 years of corporate finance experience.

“We Venture Capital is further proof of Werfen’s commitment to advancing patient care through innovation,” said Javier Gómez, financial director of the group based in L’Hospitalet de Llobregat (Barcelona). “This vehicle allows Werfen to invest in early-stage companies, understand trends in healthcare, and be at the forefront of disruptive technologies that will shape the future of diagnostics,” added the manager.

Werfen is chaired by Marc Rubiralta and in 2022 it achieved a turnover of 1.84 billion. In the largest operation in its history, the group closed the purchase of the American diagnostic company Immucor for 2 billion in March. The company’s workforce is made up of 7,000 people and its activity covers thirty countries.


(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.